Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Verticillin A is a **natural fungal metabolite** classified as an epipolythiodioxopiperazine (ETP) alkaloid, originally isolated from fungi such as *Amanita flavorubescens* with parasitic fungi *Hypomyces hyalines*. It exhibits **potent antitumor activity** in preclinical models against several cancers, including **colon cancer**, **pancreatic cancer**, and **ovarian cancer**. Verticillin A acts primarily as a **selective inhibitor of histone methyltransferases**, targeting enzymes such as SUV39H1, SUV39H2, G9a, MLL1, and GLP, resulting in the **altered methylation of histone marks** (notably H3K9 and H3K4 methylation), induction of apoptosis, and disruption of cancer cell migration and invasion[1][3][5][7]. Additional mechanisms include suppression of the c-Met pathway and its downstream effectors (Ras/Raf/MEK/ERK, AKT), and regulation of immune checkpoint molecules such as PD-L1, potentially **sensitizing tumors to immune checkpoint blockade therapy**[1][3][7]. Verticillin A is not an approved drug and is under preclinical or early-stage development as an investigational anticancer therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on verticillin A.